Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Ono Pharmaceutical Co's operating assets for the quarter that ended in Mar. 2026 was 円867,844 Mil. Ono Pharmaceutical Co's operating liabilities for the quarter that ended in Mar. 2026 was 円128,936 Mil. Ono Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2025 was 円1,084,397 Mil. Therefore, Ono Pharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.68.
Ono Pharmaceutical Co Scaled Net Operating Assets Related Terms
Ono Pharmaceutical Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co Scaled Net Operating Assets Chart
TSE:4528 vs LLY, JNJ, ABBV: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.68 mean?
Ono Pharmaceutical Co (TSE:4528) has a Scaled Net Operating Assets of 0.68 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Ono Pharmaceutical Co and its competitors.
Is Ono Pharmaceutical Co's Scaled Net Operating Assets too high?
Ono Pharmaceutical Co's current Scaled Net Operating Assets is 0.68. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Scaled Net Operating Assets compare to LLY and JNJ?
Ono Pharmaceutical Co's Scaled Net Operating Assets of 0.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current Scaled Net Operating Assets is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,245.98, compared to a current price of 円2,419.00 — trading 7.7% above its estimated fair value. The current Scaled Net Operating Assets is 0.68. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current Scaled Net Operating Assets is 0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,419.00 is trading 7.7% above its estimated GF Value™ of 円2,245.98.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
Scaled Net Operating Assets: 0.68
GF Value™: 円2,245.98 vs. price of 円2,419.00 (7.7% above fair value)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score
Get the complete analysis for TSE:4528
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
